Foamix Pharmaceuticals Ltd Logo Image

Foamix Pharmaceuticals Ltd

Most Recent Annual Report

2018 Annual Report and Form 10K

Foamix Pharmaceuticals Ltd

Foamix Pharmaceuticals Ltd has reached its limit for free report views.

Foamix Pharmaceuticals Ltd does not currently have any hardcopy reports on Click the button below to request a report when hardcopies become available.

Archived Annual Reports

About Foamix Pharmaceuticals Ltd

11-50 Employees
Based in Rehovot, Israel

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for the treatment of acne, impetigo, and other skin conditions in the United States, Germany, and Israel. Its lead product candidates include FMX101, a novel topical foam formulation which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus.

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol